Loading..
  • Oasmia logo
  • Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact
  • About Us
    • Purpose, Vision & Mission
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Collaborations and partners
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Our Science
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Portfolio
      • Docetaxel Micellar
      • XR-19
    • Animal Health
    • Research and development
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Investment case
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Contact
  • Contact
March 19, 2019

Extraordinary General Meeting 2019

Extraordinary General Meeting was held on March 19, 2019 in Oasmias offices in Uppsala.

The documentation from the Meeting is available in PDF format below.

Documents

  • Minutes
    Swedish 19 March, 2019
  • Notice
    English 5 Febuary, 2019
  • Proxy
    English 2019

Calendar

  • 19 Feb
    Year-end report May – December 2020
  • 26 Apr
    Annual Report 2020
  • 27 May
    Interim Report January – March 2021
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR-17.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Oasmia Pharmaceutical AB
Vallongatan 1, 752 28
Uppsala, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com